Filtern
Volltext vorhanden
- ja (6)
Gehört zur Bibliographie
- ja (6)
Dokumenttyp
Schlagworte
- graft versus host disease (2)
- therapeutic drug monitoring (2)
- BRAF mutation (1)
- COVID-19 (1)
- CYP2C9 (1)
- CYP3A4 (1)
- Endothelpermeabilität (1)
- Fibronektin-Bindeprotein (1)
- Ruxolitinib (1)
- SARS-CoV-2 (1)
- Staphylococcus aureus (1)
- afatinib (1)
- at-home sampling (1)
- comorbidities (1)
- critically ill patients (1)
- cytochrome P450 3A4 (CYP3A4) (1)
- dabrafenib (1)
- drug monitoring (1)
- drug–drug interactions (DDIs) (1)
- hydroxy-dabrafenib (1)
- kinase inhibitors (1)
- lasso regression (1)
- liquid chromatography tandem mass spectrometry (LC-MS/MS (1)
- melanoma (1)
- nomogram (1)
- osimertinib (1)
- pharmacokinetics (1)
- physiologically based pharmacokinetic (PBPK) modeling (1)
- population pharmacokinetics (1)
- posaconazole (1)
- risk factors (1)
- ruxolitinib (1)
- toxicity (1)
- trametinib (1)
- volumetric absorptive micro-sampling (VAMS) (1)
Institut
- Medizinische Klinik und Poliklinik II (5)
- Institut für Pharmazie und Lebensmittelchemie (4)
- Medizinische Klinik und Poliklinik I (3)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (1)
- Institut für Hygiene und Mikrobiologie (1)
- Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie (1)
Sonstige beteiligte Institutionen
Ruxolitinib (RUX) is approved for the treatment of steroid-refractory acute and chronic graft versus host disease (GvHD). It is predominantly metabolized via cytochrome P450 (CYP) 3A4. As patients with GvHD have an increased risk of invasive fungal infections, RUX is frequently combined with posaconazole (POS), a strong CYP3A4 inhibitor. Knowledge of RUX exposure under concomitant POS treatment is scarce and recommendations on dose modifications are inconsistent. A physiologically based pharmacokinetic (PBPK) model was developed to investigate the drug–drug interaction (DDI) between POS and RUX. The predicted RUX exposure was compared to observed concentrations in patients with GvHD in the clinical routine. PBPK models for RUX and POS were independently set up using PK-Sim\(^®\) Version 11. Plasma concentration-time profiles were described successfully and all predicted area under the curve (AUC) values were within 2-fold of the observed values. The increase in RUX exposure was predicted with a DDI ratio of 1.21 (C\(_{max}\)) and 1.59 (AUC). Standard dosing in patients with GvHD led to higher RUX exposure than expected, suggesting further dose reduction if combined with POS. The developed model can serve as a starting point for further simulations of the implemented DDI and can be extended to further perpetrators of CYP-mediated PK-DDIs or disease-specific physiological changes.